Cita APA (7a ed.)
Thiel, K. W., Devor, E. J., Filiaci, V. L., Mutch, D., Moxley, K., Alvarez Secord, A., . . . Leslie, K. K. (2022). Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology, 40(28), 3289-3301.
Cita Chicago Style (17a ed.)
Thiel, Kristina W., et al. "Sequencing and P53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study." Journal of Clinical Oncology 40, no. 28 (2022): 3289-3301.
Cita MLA (9a ed.)
Thiel, Kristina W., et al. "Sequencing and P53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study." Journal of Clinical Oncology, vol. 40, no. 28, 2022, pp. 3289-3301.
Precaución: Estas citas no son 100% exactas.